Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | PSMD10 | O75832 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | G6PD | P11413 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | VDR | P11473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9953154 | 0.95 | ALDH1A1 (0.46) | ALDH1A1CYP3A4CYP2C9CYP2C19STAT3 | |
| SCHEMBL1556981 | 0.89 | ALDH1A1 (0.46) | ALDH1A1CYP3A4CYP2C9CYP2C19STAT3 | |
| SCHEMBL890725 | 0.87 | ALDH1A1 (0.50) | ALDH1A1CYP3A4CYP2C9CYP2C19STAT3 | |
| SCHEMBL483847 | 0.87 | ALDH1A1 (0.50) | ALDH1A1CYP3A4CYP2C9CYP2C19STAT3 | |
| SCHEMBL4951882 | 0.85 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9CYP2C19STAT3 | |
| SCHEMBL11050599 | 0.85 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9CYP2C19STAT3 | |
| SCHEMBL4815560 | 0.85 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9CYP2C19STAT3 | |
| SCHEMBL4812770 | 0.85 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9CYP2C19STAT3 | |
| SCHEMBL8483813 | 0.85 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9CYP2C19STAT3 | |
| SCHEMBL8484861 | 0.85 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9CYP2C19STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 330 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066335-A1 | POLYSUBSTITUTED 4-HYDROXYPYRIDINE AND 4-HYDROXYQUINOLINE DERIVATIVES AS GPR84 ANTAGONISTS | UNIVERSITY OF COPENHAGEN (DK) | 2025-02-27 | — | — | US | disclosed |
| EP-4355743-A1 | POLYSUBSTITUTED 4-HYDROXYPYRIDINE AND 4-HYDROXYQUINOLINE DERIVATIVES AS GPR84 ANTAGONISTS | University of Copenhagen (DK) | 2024-04-24 | — | — | EP | disclosed |
| US-20240109894-A1 | SYNTHESIS OF 3-({5-CHLORO-1-[3-(METHYLSULFONYL)PROPYL]-1H-INDOL-2-YL} METHYL)-1-(2,2,2-TRIFLUOROETHYL)-1,3-DIHYDRO-2H-IMIDAZO[4,5-C]PYRIDIN-2-ONE | JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) | 2024-04-04 | — | — | US | disclosed |
| EP-4051662-B1 | SYNTHESIS OF 3-({5-CHLORO-1-[3-(METHYLSULFONYL)PROPYL]-1H-INDOL-2 YL}METHYL)-1-(2,2,2-TRIFLUOROETHYL)-1,3-DIHYDRO-2H-IMIDAZO[4,5-C]PYRIDIN-2-ONE | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2024-02-07 | — | — | EP | disclosed |
| CN-114630828-B | Synthesis of RSV inhibition compound | 杨森科学爱尔兰无限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20230331675-A1 | AROMATIC ETHYLENE COMPOUND AND PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230331675-A1 | AROMATIC ETHYLENE COMPOUND AND PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| WO-2022263676-A1 | POLYSUBSTITUTED 4-HYDROXYPYRIDINE AND 4-HYDROXYQUINOLINE DERIVATIVES AS GPR84 ANTAGONISTS | UNIVERSITY OF COPENHAGEN (DK) | 2022-12-22 | — | — | WO | disclosed |
| CN-109641852-B | Sulfonamides as GPR 40-and GPR 120-agonists | 东佩制药股份公司 | 2022-08-26 | — | — | CN | disclosed |
| CN-110770233-B | Fused bicyclic compound and application thereof in medicine | 广东东阳光药业有限公司 | 2022-07-26 | — | — | CN | disclosed |
| CN-101087794-A | Pharmaceutical compounds | PIRAMED LTD (GB) | 2007-12-12 | — | — | CN | disclosed |
| EP-1812445-A1 | PHARMACEUTICAL COMPOUNDS | Piramed Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| WO-2007018314-A2 | THERAPEUTIC AGENT FOR DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-15 | — | — | WO | disclosed |
| WO-2006046031-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
| US-6716847-B2 | ANTIALLERGENS, ANTIINFLAMMATORY | ASTRAZENECA AB (SE) | 2004-04-06 | — | — | US | disclosed |
| US-20030216417-A1 | Substituted anilino-quinoline compounds and use thereof | ASTRAZENECA AB | 2003-11-20 | — | — | US | disclosed |
| US-6593333-B1 | Processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines. Tumour Necrosis Factor (hereinafter TNF), for example TNF alpha , and various | ASTRAZENECA AB (SE) | 2003-07-15 | — | — | US | disclosed |
| EP-1117653-B1 | QUINOLINE AND QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CYTOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-02-05 | — | — | EP | disclosed |
| EP-1117653-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000020402-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109894-A1 | SYNTHESIS OF 3-({5-CHLORO-1-[3-(METHYLSULFONYL)PROPYL]-1H-INDOL-2-YL} METHYL)-1-(2,2,2-TRIFLUOROETHYL)-1,3-DIHYDRO-2H-IMIDAZO[4,5-C]PYRIDIN-2-ONE | HTR3C, MECP2, CDK2 | ALDH1A1 1540/4885CYP3A4 549/4885CYP2C9 2679/4885 |
| US-20250066335-A1 | POLYSUBSTITUTED 4-HYDROXYPYRIDINE AND 4-HYDROXYQUINOLINE DERIVATIVES AS GPR84 ANTAGONISTS | GPR84, GPR88, GPR65 | ALDH1A1 1304/4885CYP3A4 616/4885CYP2C9 2381/4885 |
| US-20230331675-A1 | AROMATIC ETHYLENE COMPOUND AND PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | PDCD1, CD274, PDCD1LG2 | ALDH1A1 243/4885CYP3A4 210/4885CYP2C9 343/4885 |
| US-20030216417-A1 | Substituted anilino-quinoline compounds and use thereof | IL6, IL6ST, IL1A | ALDH1A1 338/4885CYP3A4 72/4885CYP2C9 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.